New Alzheimer's drug is first to show it slows disease. But It's facing a rocky rollout | News

Eisai Co.’s breakthrough Alzheimer’s drug — the first to show it slows the brain-destroying disease — is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and

Related Keywords

Minnesota ,United States ,Mayo Clinic In Rochester ,Cambridge ,Cambridgeshire ,United Kingdom ,Houston ,Texas ,Massachusetts ,New York ,Americans ,Anna Nordvig ,Paul Schulz ,Lawrence Honig ,Eisai Leqembi ,David Knopman ,Constantine Lyketsos ,Memory Disorders Program ,Alzheimer Disease At Columbia University Medical Center ,Drug Administration ,Mcgovern Medical School ,Columbia University Irving Medical Center ,Northwestern University Feinberg School Of Medicine ,Eisai Co ,Treatment Center ,Johns Hopkins Medicine ,New York Presbyterian ,Weill Cornell Medicine Alzheimer ,Memory Disorders ,Columbia University Medical Center ,Mayo Clinic ,Allison Lapins ,Northwestern University Feinberg School ,Medicine ,Harmacology ,Hospitals ,Sychology ,Enetics ,